Skip to main content
Biocartis Group NV logo

Biocartis Group NV — Investor Relations & Filings

Ticker · BCART ISIN · BE0974281132 LEI · 549300J4HOJL5KG8HY54 BR Manufacturing
Open in API
Filings indexed 636 across all filing types
Latest filing 2019-09-23 Regulatory Filings
Country BE Belgium
Listing BR BCART

About Biocartis Group NV

https://www.biocartis.com/en

Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.

Recent filings

Filing Released Lang Actions
Press Release Biocartis NV: Five Idylla™ Performance Studies to be Presented at ‘European Society for Medical Oncology’ congress
Regulatory Filings Classification · 95% confidence The document is a press release issued by Biocartis Group NV announcing the presentation of five study posters at the ESMO Congress. It provides details on the performance of their Idylla™ assays and mentions that the abstracts are available for download on the ESMO website. As this is a general corporate announcement regarding company activities and research, and does not fit into specific financial reporting categories like 10-K or IR, it falls under the fallback category for regulatory announcements.
2019-09-23 English
Press Release Biocartis NV: Five Idylla™ Performance Studies to be Presented at ‘European Society for Medical Oncology’ congress
Regulatory Filings Classification · 95% confidence The document is a press release issued by Biocartis Group NV announcing the presentation of five study posters at the ESMO Congress. It provides details on the performance of their Idylla™ assays and mentions that the abstracts are available for download on the ESMO website. As this is a general corporate announcement regarding company activities and research, and does not fit into specific financial reporting categories like 10-K or IR, it falls under the fallback category for regulatory announcements.
2019-09-23 English
Persbericht Biocartis NV: Vijf Idylla™ performantie studies worden gepresenteerd op het ‘European Society for Medical Oncology’ (ESMO) congres
Regulatory Filings Classification · 95% confidence The document is a press release from Biocartis Group NV announcing the presentation of five study posters regarding the performance of their Idylla™ diagnostic tests at the upcoming ESMO congress. It provides summaries of research findings and links to external abstracts. It does not constitute a formal financial report, audit, or regulatory filing, but rather a corporate announcement regarding scientific/clinical progress. Under the provided definitions, this fits best as a general regulatory announcement or corporate news update, for which 'RNS' (Regulatory Filings) is the designated fallback category.
2019-09-23 Dutch
Persbericht Biocartis NV: Vijf Idylla™ performantie studies worden gepresenteerd op het ‘European Society for Medical Oncology’ (ESMO) congres
Regulatory Filings Classification · 95% confidence The document is a press release from Biocartis Group NV announcing the presentation of five study posters regarding the performance of their Idylla™ diagnostic tests at the upcoming ESMO congress. It provides summaries of research findings and links to external abstracts. It does not constitute a formal financial report, audit, or regulatory filing, but rather a corporate announcement regarding scientific/clinical progress. Under the provided definitions, this fits best as a general regulatory announcement or corporate news update, for which 'RNS' (Regulatory Filings) is the designated fallback category.
2019-09-23 Dutch
Press Release Biocartis NV: Five Idylla™ Performance Studies to be Presented at ‘European Society for Medical Oncology’ congress
Regulatory Filings Classification · 95% confidence The document is a press release issued by Biocartis Group NV announcing the presentation of five study posters at the ESMO Congress. It provides details on the performance of their Idylla™ assays and mentions that the abstracts are available for download on the ESMO website. As this is a general corporate announcement regarding company activities and research, and does not fit into specific financial reporting categories like 10-K or IR, it falls under the fallback category for regulatory announcements.
2019-09-23 English
Persbericht Biocartis NV: Vijf Idylla™ performantie studies worden gepresenteerd op het ‘European Society for Medical Oncology’ (ESMO) congres
Regulatory Filings Classification · 99% confidence The document is explicitly titled 'PERSBERICHT' (Press Release) and is dated September 23, 2019. It announces that Biocartis Group NV will present five study posters about the performance of its Idylla™ tests at the upcoming European Society for Medical Oncology (ESMO) congress. This is an announcement about scientific data presentation and product pipeline updates, not the release of full periodic financial results (ER/IR/10-K) or a formal regulatory filing like a proxy statement or insider trade report. Since it is an announcement regarding company activities, scientific findings, and future product launch expectations, it fits best under the general category for corporate announcements that are not covered by more specific codes. Given the content focuses on scientific data and product performance updates, it is a general corporate communication. It is not a Call Transcript (CT), Earnings Release (ER), or Interim Report (IR). It is a general announcement, making 'Regulatory Filings' (RNS) the most appropriate fallback for non-specific corporate news releases, although 'Investor Presentation' (IP) might seem close, this is a press release *about* presentations, not the presentation itself. However, since it details scientific findings and product pipeline news, it is a form of investor/public relations communication. Given the options, and that it is a press release announcing scientific data, 'Regulatory Filings' (RNS) serves as the best general corporate announcement category when specific PR/IR codes are not available for scientific updates. If 'RPA' (Report Publication Announcement) were used, it would imply announcing the publication of a formal report, which this is not; it announces poster presentations at a conference. Therefore, RNS is the most suitable general classification for this type of corporate news release.
2019-09-23 Dutch

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.